HAWKINS WILLIAM A 4

What Happened

• William A. Hawkins, a director of Bioventus, had 39,789 derivative units reported as exercised/converted on June 2, 2026 at $0.00 (conversion of RSUs) and the filing also reports a corresponding disposition of 39,789 derivative units the same day. On June 3, 2026 he was reported as acquiring 30,994 derivative units (RSUs) at $0.00 as a new grant.
• The $0.00 price indicates these were conversions/grants of restricted stock units (RSUs), not cash purchases or open‑market sales.

Key Details

• Transaction dates and types: 2026-06-02 — exercise/conversion of derivative (M) 39,789 shares @ $0.00 (acquired) and 39,789 shares @ $0.00 (disposed, derivative); 2026-06-03 — award/grant (A) 30,994 RSUs @ $0.00 (acquired).
• Post-transaction share ownership: not specified in the filing.
• Footnotes: F1 — each RSU represents a contingent right to one share of Class A common stock; F2 — the RSUs vested on June 2, 2026; F3 — the newly granted RSUs vest on the earlier of the first annual meeting after grant or one year from grant, subject to continued board service.
• Filing timeliness: Reported on Form 4 filed 2026-06-04 for transactions on 2026-06-02/06-03 — appears timely (Form 4 is generally due within two business days).

Context

• Transaction code M denotes exercise or conversion of a derivative — here converting vested RSUs into equity. Transaction code A denotes an award/grant of RSUs.
• These entries reflect vesting/conversion and a new RSU grant (non‑cash events). Such transactions are routine compensation/vesting actions and are not the same as an open‑market purchase or sale by the insider.